NCT04504071 2025-09-08
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
Shanghai Chest Hospital
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT04027647 2025-06-12
Phase 2 Study of Dacomitinib in NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT04946968 2025-06-11
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
National Cancer Centre, Singapore
Phase 2 Active not recruiting